Osimertinib Recruiting Phase 1 / 2 Trials for NSCLC (Non-small Cell Lung Carcinoma) / Lung Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

RecruitingTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT03567642A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
NCT03891615Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
NCT03255083DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
NCT03535363Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
NCT03050411Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer